An open trial of ceftazidime in the treatment of complicated urinary tract infections

In an open prospective trial, twenty-two patients (twenty-one males and one female) with complicated urinary tract infections were treated with 2 g of ceftazidime every 12 hours (nineteen patients were treated intramuscularly and three intravenously for 7 or 10 days). The weight, age and underlying disorders of the urinary tract are indicated for each patient, as well as infecting pathogens and corresponding MICs. Clinical cure, as defined by complete resolution of symptoms and signs was obtained in all the patients. The over all bacteriological clearance rate was 93.3%. Four out of five Pseudomonas aeruginosa infections were cleared. There were no adverse events during ceftazidime treatment except for slight pain around the site of intramuscular injection. No changes in laboratory parameters attributable to ceftazidime therapy were noted. Ceftazidime is a safe and effective drug in the treatment of complicated urinary tract infections.

Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease

In a group of patients with Parkinson disease there was no difference in plasma DBH activity between cases treated with L-Dopa and not treated. These patients tend to have an elevated activity of erythrocyte AChE.